Xencor Inc at Barclays Global Healthcare Conference Transcript
Hello again, everyone. My name is Etzer Darout. I'm one of the senior biotech analysts at Barclays. My pleasure to welcome Xencor to our fireside chat. With us today, we have Bassil Dahiyat, President and Chief Executive Officer; Dane Leon, Executive Vice President of Strategy.
And so thank you, guys, for joining us today. Maybe, Bassil, just to kick us off, just give us a broad overview of Xencor and some of the milestones that you would like to hit in 2026.
So Xencor is a company that was founded around really world-leading protein engineering technology. We've established ourselves over the last couple of decades as people who can create antibodies that can truly have best-in-class properties. There's multiple marketed products we've built our technologies used widely around pharma to have created a broad pipeline in oncology, autoimmune disease and other areas.
Right now, we're focused on building
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
